Log in or Sign up for Free to view tailored content for your specialty!
Alzheimer's Disease/Cognition News
Statins may lower risk for any dementia among adults with heart failure
Researchers reported that a population-based study shows statin use among older adults with heart failure was associated with a 20% lower risk for all-cause dementia, including a 28% reduction in risk for developing Alzheimer’s disease.
Phase 3 study of agitation drug fails to achieve primary efficacy endpoint
Otsuka has announced that a phase 3 clinical trial of AVP-786, a combination therapy to treat agitation associated with dementia due to Alzheimer’s disease, failed to achieve its primary endpoints.
Log in or Sign up for Free to view tailored content for your specialty!
Biopharma firm raises $30M to advance neuro, derm tyrosine kinase 2 inhibitors
An Indianapolis-area biopharmaceutical company announced it has raised $30 million in Series B financing to advance investigational tyrosine kinase 2 inhibitors for multiple sclerosis as well as dermatologic conditions.
Biotherapeutic company raises $120M to advance drug-resistant epilepsy treatment
A biotherapeutics company has raised $120 million to advance its pipeline of cell therapies, including a lead investigational regenerative neural cell therapy candidate to treat drug-resistant mesial temporal lobe epilepsy.
Coronary artery calcium score may predict aging trajectory for older adults
Older adults with a coronary artery calcium score of 0 had more favorable aging indices, including normal cognitive function, vascular function and better hearing, compared with those with CAC scores of 1,000 or greater, data show.
Diabetes management program in primary care reduces risk for dementia
A program geared toward diabetes management in the primary care setting helped to reduce patients’ risk for dementia — including Alzheimer’s disease — according to researchers.
Physical activity reduces cognitive decline but not significantly, researchers find
Physical activity was only minimally associated with a reduced risk for cognitive decline or impairment. Even so, the finding was still significant from a population health perspective, according to researchers.
Silo Pharma announces roster of drugs in development for mental health, chronic pain
Silo Pharma will advance a portfolio of four drugs in its 2024 clinical pipeline, targeting conditions related to mental health, chronic pain and neurology.
Biogen announces discontinuation of Aduhelm
Biogen announced a reprioritization of resources regarding its pipeline of therapeutics to address Alzheimer’s disease, deciding to discontinue development of Aduhelm and choosing to advance Leqembi.
Isaac Health raises $5.7M to address gaps in US dementia care
Isaac Health has raised $5.7 million to help identify and care for individuals with different cognitive and brain health conditions in the United States.
-
Headline News
Race, sex disparities persist in weight-loss surgery
January 16, 20253 min read -
Headline News
Survey reveals ‘disproportionate barriers’ to success among Latina physicians
January 16, 20252 min read -
Headline News
Study shows intentional strategies enhance recruitment, retainment of diverse populations
January 14, 20252 min read
-
Headline News
Race, sex disparities persist in weight-loss surgery
January 16, 20253 min read -
Headline News
Survey reveals ‘disproportionate barriers’ to success among Latina physicians
January 16, 20252 min read -
Headline News
Study shows intentional strategies enhance recruitment, retainment of diverse populations
January 14, 20252 min read